PROK1 Expression Is Associated With Prognosis and May Influence Response to Antiandrogen Therapy in Prostate Cancer
Ding-jin Lu, Hai-qi Liang, Yu-jian Li, Jia-yin Yu, Li-wei Wei, Qi-zhou Mo, Jia-wen Zhao, Ren-jun Nong, Yao-yu Wang, Xiao-ping Zhang, Min Qin, Ji-wen Cheng · 2026
Read PROK1 Expression Is Associated With Prognosis and May Influence Response to Antiandrogen Therapy in Prostate Cancer by Ding-jin Lu, Hai-qi Liang, Yu-jian Li, Jia-yin Yu, Li-wei Wei, Qi-zhou Mo, Jia-wen Zhao, Ren-jun Nong, Yao-yu Wang, Xiao-ping Zhang, Min Qin, Ji-wen Cheng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13621831.txt.
Description
Ding-jin Lu leads a large author group studying a gene called PROK1 in prostate cancer. Earlier work tied the gene to tumour growth, so the team asked whether its activity level predicts how patients fare. They also checked responses to antiandrogen therapy, a treatment that blocks male hormones. Data came from public cancer databases holding hundreds of patient samples.
The analysis found less PROK1 activity in tumours than in normal tissue, with levels dropping further as cancers advanced. Single-cell data placed the gene mainly in a support cell type within the tumour, where it seemed to signal to cancer cells through a related growth pathway. Tumours with higher PROK1 responded better to the drug bicalutamide, yet treatment itself lowered PROK1 over time. The authors link that drop to growing drug resistance and propose the gene as a marker worth testing in care.
Catalog record
| CREATOR | Ding-jin Lu, Hai-qi Liang, Yu-jian Li, Jia-yin Yu, Li-wei Wei, Qi-zhou Mo, Jia-wen Zhao, Ren-jun Nong, Yao-yu Wang, Xiao-ping Zhang, Min Qin, Ji-wen Cheng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |